Revolution Medicines is a Redwood City, Calif.-based clinical-stage company focused on discovery and development of novel small-molecule inhibitors against frontier oncology targets in the RAS and related PI3K/AKT/mTOR pathways. The company closed a $100M Series C equity financing to support continued advancement of its pipeline. Its lead clinical program, RMC-4630, is an orally bioavailable SHP2 inhibitor being evaluated in a Phase 1/2 program and is the subject of an exclusive global research, development and commercialization agreement with Sanofi. Other programs include a KRASG12C(GTP) program in lead optimization, a 4EBP1/mTORC1 program with development candidate RMC-5552 advancing into IND-enabling studies, and a discovery-stage SOS1 program. Proceeds from the financing will be used to advance these programs toward clinical development. REVOLUTION Medicines discovers and develops drugs directed at frontier oncology targets. Its R&D pipeline includes programs targeting SHP2 (PTPN11), SHP1 (PTPN6) and 4EBP1, which regulate cancer signaling, the immune response and oncogene translation in the PI3K/AKT/mTOR pathway. The company has highlighted progress in its SHP2 program, including multiple presentations at the recent AACR conference. To support its programs and general business activities, REVOLUTION Medicines announced a $56 million Series B financing. The company also expanded its leadership team with appointments of Ryan Martins (CFO), Xiaolin Wang, D.Sc. (SVP, clinical development) and Hirdesh Uppal, D.V.M., Ph.D. (VP, development sciences). REVOLUTION Medicines is privately financed by top-tier investors and is headquartered in Redwood City, Calif. REVOLUTION Medicines discovers and develops drugs directed at frontier oncology targets, drawing inspiration from natural products and evolution. The company deploys an integrated toolkit including REVBLOCKS™ modular synthesis methodologies and the REVEAL™ computational platform to guide drug design for non-classical targets. Proceeds from the recent financing will support advancement of multiple discovery programs toward clinical development. The company is privately financed by top-tier investors and emphasizes a combination of biology and chemistry to address unmet needs in cancer. REVOLUTION Medicines is headquartered in Redwood City, California, at the intersection of Silicon Valley and the birthplace of biotechnology. REVOLUTION Medicines was launched with a $45 million Series A to reconfigure complex natural products into pharmaceutically optimized medicines. The company uses a building-block synthesis platform developed by Martin D. Burke to assemble natural product–like structures rapidly and at scale. It has an exclusive license from the University of Illinois to practice and expand Burke’s technology. REVOLUTION Medicines’ lead programs are antifungal candidates that leverage the amphotericin B scaffold while aiming to separate antifungal efficacy from human kidney toxicity. The company is pursuing a rapid clinical development path for these lead candidates. The founding team is led by CEO Mark A. Goldsmith and includes founding CSO David Pompliano, with Burke serving as founder and scientific advisory board chairman. Third Rock Ventures is the firm that launched and backs the company.

Total raised

$226M

Funding rounds

4

Latest round

Series C

Latest activity

Jul 2019